A global increase of using pharmaceutical partnerships to speed up the lab-to-market process

LONDON - May 2, 2014 - PRLog -- In the past 12 months the number of biosimilar development projects has risen dramatically and is expected to continue to grow in the upcoming years. Based on this, the SMi group is delighted to announce its inaugural European BioNetworks Summit taking place in London on the 29^th-30^th of September 2014.

This important and timely meeting will allow biotech, pharma, academic and funding organisationsto evaluate how they partner with other stakeholders in the field to accelerate research and reduce costs.

Hear all about the ways to benefit from the increasing changes in the market at SMi’s European Bionetworks conference.

2 days, over 16 unique presentations, hours of networking and 3 Exciting Round Table Discussions, a Panel Discussion and an interactive workshop:

·         "Six things every business development person should know about improving licensing outcomes" lead by Timothy Herpin , Head of Transactions (UK) Business Development, AstraZeneca

·         "Co-developing with academia...an academics perspective!" by Professor Joseph Sweeney,Professor of Catalysis and Chemical Biology, Department of Chemical Sciences, University of Huddersfield

·         "The big question! - How to get noticed by the big league players" by Lubor Gaal, Head of Europe Business Development, Bristol-Myers Squibb

·         Panel Discussion: "The 4 musketeers…'one for all and all for one' — how can pharma, biotech, academia and venture capitalists live by this motto!"
Panelists:
Lubor Gaal, Head of Europe, Business Development, Bristol-Myers Squibb
Timothy Herpin, Head of Transactions (UK), Business Development, AstraZeneca
Jorgen Drejer, Chief Executive Officer, Aniona
Robert Williams, Chief Development Scientist, Drug Development Office, Cancer Research UK
Joseph Sweeney, Professor of Catalysis and Chemical Biology, Department of Chemical Sciences , University of Huddersfield
Sofia Ioannidou, Investment Director, Edmond de Rothschild Investment Partners

Interactive half-day post-conference workshop: "Cost Effective Pathway to Early Clinical Development to Support Regulatory Approvals and Commercial Partnering", lead by Carla Bennett, Senior Clinical Research Consultant, and Dr Sarah Nicholson, Senior Regulatory Consultant, QRC Consultants Ltd

Debate about the latest developments pertaining to strategic partnering and funding such as the recent Novartis portfolio transformation through the acquisition of GSK's oncology products. Plus a joint venture between Novartis OTC and GSK's Consumer Business.

For more information, go to www.smi-online.co.uk/bio-networks37.asp

Contact for media partners: Julia Rotar, marketing manager, jrotar@smi-online.co.uk

Alternatively, contact Fateja Begum on +44 (0) 207 827 6184 or e-mail fbegum@smi-online.co.uk